During the corresponding time, Arbutus Biopharma Corp saw a revenue deteriorated by -90.56 % year on year, sequentially revenue fell by -99.43 %. While revenue at the Arbutus Biopharma Corp's corporate clients
Arbutus Biopharma's Comment on Sales, Marketing and Customers
The company operates within the pharmaceutical sector, serving customers who bill federal healthcare programs for products, including physicians who prescribe these products. Its interactions involve government healthcare programs such as Medicare, Medicaid, and the Children’s Health Insurance Program. The market segments include healthcare providers such as physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives, and teaching hospitals. Additionally, the company engages with private third-party payors, including private insurers, which are subject to various federal and state laws and regulations.
Treatment with Arbutus Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg LevelsData highlighted in oral presentation at the European Association for the Study of the Liver (EASL) CongressArbutus Pharmaceuticals, a leading biopharmaceutical company focused on discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B virus (HBV) infection, announced that their investigational RNAi therapeutic, Arbutus Imdusiran, in combination with VTP-300, has achieved statistical significance in lowering hepatitis B surface antigen (HBsAg) levels.The groundbreaking data presented at the European Association for the Study of the Liver (EASL) Congress proved the...
In the field of Hepatitis B Virus (HBV) research, one of the major challenges has been achieving sustained undetectable levels of Hepatitis B surface antigen (HBsAg), which is considered a crucial requirement for functional cure. However, a recent study conducted by Arbutus Biopharma Corp presents a potential breakthrough in this area using a combination of Arbutus Imdusiran, interferon (IFN) therapy for a short duration, and ongoing nucleoside analogue (NA) therapy. This article aims to interpret the findings of this study and assess its impact on the company.Interpreting the Findings:The study involved administering imdusiran for 48 weeks, IFN for 24 weeks, and continued NA therapy. Remarkably, at the end ...
Arbutus Biopharma Corp: Charting a Bright Future with Groundbreaking RNAi TherapeuticArbutus Biopharma Corp, a leading biotechnology company, has recently unveiled its ambitious corporate objectives for 2024, along with an exciting financial update. The company aims to revolutionize the field of medicine with the development of its RNAi therapeutic, imdusiran, which is showing promising results in two ongoing Phase 2a clinical trials. Arbutus anticipates imdusiran to become a cornerstone therapy when used in combination with other compounds, a breakthrough that is expected to be realized by 2024.The use of RNA interference (RNAi) technology has taken the medical world by storm, promising targeted and efficie...
Arbutus Biopharma’s Comment on Sales, Marketing and Customers
The company operates within the pharmaceutical sector, serving customers who bill federal healthcare programs for products, including physicians who prescribe these products. Its interactions involve government healthcare programs such as Medicare, Medicaid, and the Children’s Health Insurance Program. The market segments include healthcare providers such as physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives, and teaching hospitals. Additionally, the company engages with private third-party payors, including private insurers, which are subject to various federal and state laws and regulations.
Sources:
Arbutus Biopharma Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Arbutus Biopharma Corp’s corporate clients.
For your research, we’ve provided 9 tables on Arbutus Biopharma Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
35.6 %